Interleukin‐17 receptor A blockade with brodalumab in palmoplantar pustular psoriasis: Report on four cases. Issue 5 (20th February 2019)

• Record Type: Journal Article
• Authors: Pinter, Andreas; Wilsmann‐Theis, Dagmar; Peitsch, Wiebke K.; Mössner, Rotraut
• Is Part Of: Journal of dermatology. Volume 46:Issue 5(2019)
• Page Start: 426
• Page End: 430
• Publication Date: 2019-02-20
• Subjects: brodalumab -- interleukin‐17 A -- interleukin‐17 receptor A -- palmoplantar pustular psoriasis -- pustulosis palmoplantaris; Dermatology -- Periodicals; Dermatology -- Japan -- Periodicals; Skin -- Diseases -- Periodicals; 616.5005
• DOI: 10.1111/1346-8138.14815
• Languages: English
• ISSNs: 0385-2407

Abstract

Abstract: Palmoplantar pustular psoriasis, also termed palmoplantar pustulosis (PPP), is a rare disease affecting the palmoplantar regions characterized by sterile, yellow to brown pustules mostly on erythematous skin. PPP is related to a high burden due to painful, impaired and stigmatizing character. Several isoforms of interleukin (IL) have been implicated in its pathophysiology. Here, we report on four patients with PPP treated with the novel IL‐17 receptor A blocker brodalumab, in whom this therapy was not successful or showed moderate improvement combined with adverse events.